On the heels of closing six facilities in 2025, the company has moved its headquarters from San Diego to Ohio with a focus on biologics and aseptic drug product manufacturing.
The connected manufacturing environment is meant to enable manufacturers to scale production to commercially viable levels without replacing existing processes.
The expanded collaboration adds commercial-compliant packaging and distribution for MCO-010, an optogenetic gene therapy targeting retinal degenerative diseases.
